RxDoctor Payments Data

Sridevi Bhumi, MD

Gastroenterology · Garden City, NYNPI 1306906938

Payments from drug & device makers

$17,199in general payments, 2019–2025

Across 821 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • AbbVie$2K
  • QOL Medical, LLC$2K
  • Ardelyx, Inc.$1K
  • Nestle Healthcare Nutrition Inc.$1K
  • Bristol Myers Squibb$1K
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$16,93098%
  • Education$90%
  • Other$2602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,199 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$63,726
Medicare patients
194
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide271$299,314
CreonLipase/Protease/Amylase33$47,881
XifaxanRifaximin14$28,571
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br12$24,342
Sucralfate610$20,082
TrulancePlecanatide17$17,274
Famotidine561$13,929
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates228$13,274
Dexlansoprazole DrDexlansoprazole27$9,672
Mesalamine27$9,515
PentasaMesalamine13$8,110
Pantoprazole Sodium588$7,008
Dicyclomine Hcl106$1,833
Omeprazole102$1,550
Rabeprazole Sodium11$731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,458$347,195304 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$3,287$45,84531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →